The agency tasked with amplifying some of the most consequential science happening anywhere in medicine just got a new mandate. FINN Partners has been named global agency of record for the AD/PD™ Conference, the world’s leading international gathering dedicated to research on Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative conditions, according to a PR Newswire announcement. The appointment puts one of the largest independent global marketing agencies in charge of shaping how this science reaches the press, the public, and the broader medical community. For a field where public awareness can directly accelerate research funding and patient advocacy, that communications infrastructure matters enormously.
Neurodegenerative disease sits at one of the most urgent intersections of science and public health. Alzheimer’s disease alone affects an estimated 55 million people worldwide, a number the World Health Organization projects will nearly triple by 2050. The AD/PD Conference draws thousands of researchers, clinicians, and biopharma executives annually to exchange findings on disease mechanisms, biomarkers, and emerging therapies. Getting that science out of the conference hall and into meaningful public discourse is precisely the challenge FINN Partners is now being asked to solve. It is a role that resonates with broader efforts to connect biomedical breakthroughs to the people they could help, similar to the mission behind patient-centered biomedical recognition efforts like the Prix Galien’s new Michael J. Fox award.
What FINN Partners Brings to the Table
FINN Partners is not a boutique health PR shop. The firm operates across more than 30 offices globally and runs a dedicated health practice that spans pharmaceuticals, medical devices, and scientific communications. Being named agency of record for AD/PD means the firm will handle media relations, strategic communications, and stakeholder engagement across the conference’s international footprint. That includes reaching scientific press, patient advocacy organizations, and policymakers who increasingly set the regulatory and funding conditions for neurodegeneration research.
The scope of the assignment reflects how seriously the scientific conference world is now treating its communications function. AD/PD is not a trade show — it is a peer-driven research forum where data first presented on stage can move financial markets, shift clinical trial recruitment, and reframe treatment paradigms. The agency’s role is to ensure that signal does not get lost in the noise of a crowded medical media landscape. FINN Partners’ health team will need to translate dense trial data and mechanistic findings into narratives that resonate far beyond the neuroscience community.
Why This Appointment Signals a Shift in Science Communication
The decision to retain a global agency of record — rather than rely on in-house or regional communications support — reflects a growing recognition that scientific conferences must compete for attention the same way any major institution does. The AD/PD Conference has historically been the venue where landmark research on amyloid, tau, and alpha-synuclein pathology has been presented to the world. With disease-modifying therapies for Alzheimer’s now reaching regulatory approval for the first time in decades, the stakes for accurate, timely, and far-reaching communications have never been higher.
FINN Partners enters this role at a moment when the neurodegenerative disease field is generating some of its most consequential data in a generation. New biomarker-based diagnostic tools, blood tests capable of detecting Alzheimer’s pathology years before symptoms emerge, and a pipeline of next-generation therapeutics are all converging. The agency’s mandate will be to ensure that when those findings land at AD/PD, the story reaches the audiences who can act on it — investors, regulators, patient groups, and journalists. In a landscape where technology narratives often crowd out medical science in the public conversation, that kind of dedicated communications infrastructure is not a luxury. It is a strategic necessity.
